文献速递其他结缔组织病

英国系统性硬化症与癌症:基于临床实践研究数据链的流行病学分析

Systemic sclerosis and cancer in the UK: an epidemiological analysis using the clinical practice research datalink.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

利用英国临床实践研究数据链(CPRD)识别1588例系统性硬化症(SSc)患者,队列研究显示SSc诊断后癌症发生风险升高(现患队列调整HR 1.41,95%CI 1.14-1.75;新发队列调整HR 1.32,95%CI 1.04-1.67),病例对照研究未发现SSc诊断前癌症风险增加。

要点

  • SSc诊断后癌症发生风险升高,现患队列调整HR 1.41(95%CI 1.14-1.75),新发队列调整HR 1.32(95%CI 1.04-1.67)。
  • SSc患者癌症总体发生率为17.6/1000人年,非SSc组为13.9/1000人年。
  • 病例对照研究未发现SSc诊断前癌症风险增加,作者认为 findings 可支持SSc癌症筛查建议。

核心结论

  • SSc诊断后癌症诊断风险增加,而SSc诊断前癌症风险未增加,作者认为该发现可支持SSc患者的癌症筛查建议。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的队列研究,采用经验证的病例确认策略识别SSc患者,按年龄、性别和全科诊所与6名非SSc对照匹配,现患和新发SSc病例分别分析。
  • 同时进行1:6匹配的病例对照研究,考察SSc诊断前癌症发生情况。

主要发现

  • 最常见癌症为皮肤黏膜癌(4.5%)、肺癌(2.1%)和乳腺癌(1.9%)。
  • SSc患者癌症发生比例显著高于非SSc者:新发队列11.2% vs 9.7%(P=0.02),现患队列14.8% vs 12.1%(P=0.03);现患队列肺癌为2.6% vs 0.9%(P<0.001)。
  • SSc组癌症总体发生率为17.6/1000人年,非SSc组为13.9/1000人年。
  • 现患SSc调整HR为1.41(95%CI 1.14-1.75),新发SSc调整HR为1.32(95%CI 1.04-1.67);病例对照研究未发现SSc诊断前癌症风险增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cancer can cause mortality in systemic sclerosis (SSc). We investigated the association between cancer and SSc using the Clinical Practice Research Datalink (CPRD). METHODS: A validated case-ascertainment strategy identified SSc patients in the CPRD. A cohort study design examined cancer occurrence following SSc, with SSc patients matched to six non-SSc comparators by age, sex and GP practice. Prevalent and incident cases of SSc were analysed separately. Descriptive statistics and Cox analyses determined hazard ratios for cancer occurrence. A case-control study (matched 1:6) examined cancer occurrence prior to SSc. RESULTS: From 10.1 million individuals in CPRD, 1588 of cases of SSc were identified. Two hundred and six cancers followed SSc diagnosis (116 in prevalent and 90 in incident cohort). Commonest cancers were mucocutaneous (4.5%), lung (2.1%) and breast (1.9%). The proportion of SSc patients developing cancer was significantly higher than non-SSc in both incident (11.2% vs 9.7%, P = 0.02) and prevalent cohorts (14.8% vs 12.1%, P = 0.03); particularly for lung cancer (2.6% vs 0.9% in prevalent cohort, P < 0.001). Overall incidence of cancer in the SSc groups was 17.6/1000 person years, compared with 13.9/1000 person years in the non-SSc group. The adjusted hazard ratios for cancer were 1.41 (95% CI 1.14-1.75) and 1.32 (95% CI 1.04-1.67) for prevalent and incident SSc, respectively. No increased risk of cancer prior to SSc diagnosis was identified in the case-control study. CONCLUSION: We have identified an increased risk of cancer diagnosis following, but not before, SSc diagnosis. Our findings could support screening recommendations for cancer in SSc.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pauling JD, McHugh NJ, McGrogan A, et al. Systemic sclerosis and cancer in the UK: an epidemiological analysis using the clinical practice research datalink. Rheumatology (Oxford). 2025. PMID: 39137146. doi:10.1093/rheumatology/keae433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。